Filing Flows › Intellia Therapeutics (NTLA) › Q3 2026 › vs Q2 2026
Intellia Therapeutics (NTLA) Q3 2026 vs Q2 2026 (quarter over quarter)
Intellia Therapeutics's revenue fell $496K (-6%) from $7.7M in Q2 2026 to $7.2M in Q3 2026.
Intellia Therapeutics, Q3 2026: revenue $7.2M (-48% year over year), net loss $127M, operating cash flow −$85.4M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $7.2M | $7.7M | −$496K | -6% |
| Net loss | $127M | $107M | $20.9M | +20% |
| Costs & expenses | $135M | $120M | $14.2M | +12% |
| Operating costs | $129M | $120M | $9.1M | +8% |
| Interest & other, net | $5.2M | −$6.1M | $11.3M | — |
| Research & development | $83.3M | $82.6M | $751K | +0.9% |
| General & admin | $46.1M | $37.8M | $8.3M | +22% |
| Operating cash sources | $127M | $107M | $20.9M | +20% |
| Depreciation & amortization | $1.9M | $2.1M | −$200K | -10% |
| Share-based compensation | $14.4M | $18.1M | −$3.7M | -20% |
| Working capital & other | $25.8M | $3.3M | $22.4M | +670% |
| Cash used in operations | $85.4M | $83.1M | $2.3M | +3% |
| Net loss absorbed | $127M | $107M | $20.9M | +20% |
Questions
How much did Intellia Therapeutics's revenue grow quarter over quarter in Q3 2026?
Intellia Therapeutics's revenue fell $496K (-6%) from $7.7M in Q2 2026 to $7.2M in Q3 2026.